DK2656070T3 - Bestemmelse af en levende rekombineret anti-mycobakteriel vaccinationseffektivitet - Google Patents
Bestemmelse af en levende rekombineret anti-mycobakteriel vaccinationseffektivitet Download PDFInfo
- Publication number
- DK2656070T3 DK2656070T3 DK11805020.2T DK11805020T DK2656070T3 DK 2656070 T3 DK2656070 T3 DK 2656070T3 DK 11805020 T DK11805020 T DK 11805020T DK 2656070 T3 DK2656070 T3 DK 2656070T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- vaccine
- rbcg
- immune response
- vaccination
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (11)
1. Fremgangsmåde til bestemmelse af en rekombineret mycobakteriel levende vaccines effektivitet, omfattende bestemmelse af det T-helper-type-17 (Th17) immunsvar i et vaccineret emne, hvorved et detekterbart Th17-immunsvar er indikativ for beskyttende immunitet i emnet.
2. Fremgangsmåde ifølge krav 1, hvorved vaccinen er en rekombineret myco-bakterie, som omfatter et rekombineret nucleinsyremolekyle, som koder for en fusionpolypeptid, der omfatter (a) et domæne, der er i stand til at fremkalde et immunsvar, og (b) et phagolysosomalt escape-domæne.
3. Fremgangsmåde ifølge krav 2, hvorved mycobakterien er en urease-fattig.
4. Fremgangsmåde ifølge krav 3, hvorved mycobakterien er rBGAUreC :: Holy* :: Hyg+.
5. Fremgangsmåde ifølge krav 1, hvorved vaccinen er en underenhedsvaccine.
6. Fremgangsmåde ifølge ethvert af kravene 1 - 5, hvorved vaccinen er en vaccine imod mycobakterielle infektioner, især mycobakterielle lungeinfektioner og især tuberkulose.
7. Fremgangsmåde ifølge ethvert af kravene 1 - 6, hvorved bestemmelsen af Th17-immunsvaret omfatter udsættelse af en prøve omfattende immunceller fra det vaccinerede emne for en restimulation med en antigen, som svarer til antigenet i vaccinen og bestemmelse af tilstedeværelsen og/eller mængden af Th17-immunsvar-associerede celler i prøven.
8. Fremgangsmåde ifølge ethvert af kravene 1 - 6, hvorved bestemmelsen af Th-17-immunsvaret omfatter bestemmelse af IL17, f.eks. ved immunologiske metoder.
9. Fremgangsmåde ifølge ethvert af kravene 1 - 8, hvorved emnet er et pattedyr, f.eks. et menneske.
10. Fremgangsmåde ifølge ethvert af kravene 1 - 9, hvorved Th17-immunsvaret bestemmes 20 - 50 dage efter vaccinationen.
11. Anvendelse af reagenskit i fremgangsmåden ifølge ethvert af kravene 1-10 til bestemmelsen afen rekombineret mycobakteriel levende vaccines effektivitet, omfattende (a) en reagens til restimulering af immunceller fra et tidligere vaccineret emne, og (b) en reagens til detektering af et Th17-immunsvar.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061425442P | 2010-12-21 | 2010-12-21 | |
| PCT/EP2011/073609 WO2012085099A1 (en) | 2010-12-21 | 2011-12-21 | Determination of the efficacy of an anti-mycobacterial vaccination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2656070T3 true DK2656070T3 (da) | 2016-06-13 |
Family
ID=45446021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11805020.2T DK2656070T3 (da) | 2010-12-21 | 2011-12-21 | Bestemmelse af en levende rekombineret anti-mycobakteriel vaccinationseffektivitet |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8906389B2 (da) |
| EP (1) | EP2656070B9 (da) |
| JP (1) | JP6055780B2 (da) |
| KR (1) | KR101882040B1 (da) |
| CN (1) | CN103492877B (da) |
| AU (1) | AU2011347266B2 (da) |
| BR (1) | BR112013015878B1 (da) |
| CA (1) | CA2822715C (da) |
| CU (1) | CU20130084A7 (da) |
| CY (1) | CY1117412T1 (da) |
| DK (1) | DK2656070T3 (da) |
| EA (1) | EA029833B9 (da) |
| ES (1) | ES2569035T3 (da) |
| HK (1) | HK1192322A1 (da) |
| HR (1) | HRP20160558T1 (da) |
| HU (1) | HUE027781T2 (da) |
| MX (1) | MX345961B (da) |
| PL (1) | PL2656070T3 (da) |
| PT (1) | PT2656070E (da) |
| RS (1) | RS54770B1 (da) |
| SG (1) | SG191331A1 (da) |
| SI (1) | SI2656070T1 (da) |
| SM (1) | SMT201600149B (da) |
| UA (2) | UA113282C2 (da) |
| WO (1) | WO2012085099A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3543698A1 (en) * | 2018-03-20 | 2019-09-25 | Helmholtz-Zentrum für Infektionsforschung GmbH | Method for determining vaccine efficacy in an individual and means therefore |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0902086A1 (en) | 1997-08-22 | 1999-03-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Tuberculosis vaccine |
| EP1137769B1 (en) * | 1998-11-10 | 2008-09-03 | University Of Rochester | Methods for the generation of dna libraries |
| GB9923309D0 (en) * | 1999-10-01 | 1999-12-08 | Glaxo Group Ltd | Assay |
| JP2001215224A (ja) * | 1999-11-25 | 2001-08-10 | Hitachi Chem Co Ltd | 免疫反応のアッセイ法、免疫学的判定法及びアッセイキット |
| CA2523084C (en) | 2003-04-23 | 2012-09-04 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Tuberculosis vaccine with improved efficacy |
| AU2006214473A1 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor |
| US20080031882A1 (en) * | 2006-06-19 | 2008-02-07 | Liang Spencer C | Methods of modulating IL-22 and IL-17 |
| CN101329230B (zh) * | 2008-07-14 | 2010-10-20 | 中国人民解放军第三军医大学 | 改进的免疫荧光细胞染色方法 |
| JP2010051307A (ja) * | 2008-07-28 | 2010-03-11 | Eisai R & D Management Co Ltd | Ｔｈ１７細胞およびＴｒｅｇ細胞の分化誘導を調節する物質のスクリーニング方法 |
| DK2341928T3 (da) * | 2008-10-20 | 2015-09-28 | Univ Zürich | Mycobacterium tuberculosis-vaccine |
| BRPI1011919A2 (pt) * | 2009-06-29 | 2017-09-26 | Childrens Medical Center | vacinas e composições contra streptococcus pneumoniae |
-
2011
- 2011-12-21 WO PCT/EP2011/073609 patent/WO2012085099A1/en active Application Filing
- 2011-12-21 EA EA201300738A patent/EA029833B9/ru not_active IP Right Cessation
- 2011-12-21 HU HUE11805020A patent/HUE027781T2/en unknown
- 2011-12-21 EP EP11805020.2A patent/EP2656070B9/en active Active
- 2011-12-21 BR BR112013015878-6A patent/BR112013015878B1/pt active IP Right Grant
- 2011-12-21 SG SG2013048756A patent/SG191331A1/en unknown
- 2011-12-21 US US13/996,832 patent/US8906389B2/en active Active
- 2011-12-21 SI SI201130785A patent/SI2656070T1/sl unknown
- 2011-12-21 CA CA2822715A patent/CA2822715C/en active Active
- 2011-12-21 JP JP2013545368A patent/JP6055780B2/ja active Active
- 2011-12-21 PL PL11805020T patent/PL2656070T3/pl unknown
- 2011-12-21 AU AU2011347266A patent/AU2011347266B2/en active Active
- 2011-12-21 UA UAA201308661A patent/UA113282C2/uk unknown
- 2011-12-21 PT PT118050202T patent/PT2656070E/pt unknown
- 2011-12-21 CN CN201180066448.8A patent/CN103492877B/zh active Active
- 2011-12-21 KR KR1020137019197A patent/KR101882040B1/ko active IP Right Grant
- 2011-12-21 ES ES11805020.2T patent/ES2569035T3/es active Active
- 2011-12-21 UA UAA201308660A patent/UA112067C2/uk unknown
- 2011-12-21 MX MX2013007244A patent/MX345961B/es active IP Right Grant
- 2011-12-21 DK DK11805020.2T patent/DK2656070T3/da active
- 2011-12-21 RS RS20160350A patent/RS54770B1/sr unknown
-
2013
- 2013-06-21 CU CU2013000084A patent/CU20130084A7/es unknown
-
2014
- 2014-06-13 HK HK14105616.7A patent/HK1192322A1/xx unknown
-
2016
- 2016-04-25 CY CY20161100335T patent/CY1117412T1/el unknown
- 2016-05-24 HR HRP20160558TT patent/HRP20160558T1/hr unknown
- 2016-05-31 SM SM201600149T patent/SMT201600149B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9879268B2 (en) | Recombinant Mycobacterium as a vaccine | |
| Verreck et al. | Variable BCG efficacy in rhesus populations: Pulmonary BCG provides protection where standard intra-dermal vaccination fails | |
| DK2656070T3 (da) | Bestemmelse af en levende rekombineret anti-mycobakteriel vaccinationseffektivitet | |
| Wilkinson et al. | Novel vaccines against tuberculosis | |
| Maggioli et al. | A manuscript published at Plos One | |
| Dockrell | T cell protective immune responses against TB | |
| Govender | Development of novel T cell assays and assessment of immune recognition to latency associated M. tuberculosis-specific antigens Rv2660 and Rv2659 | |
| Lutwama | Comparison of immune responses induced by Bacillus calmette-Guerin when given at birth or at 6 weeks of age in Ugandan Infants | |
| LIAN | Identification of immune correlates of protection in tuberculosis infection | |
| Dockrell et al. | BCG Vaccination: Epidemiology and Immunology | |
| Dowall | Immune responses to BCG immunisation and Mycobacterium tuberculosis infection in non-human primates |